Tata Sons, now debt-free, has asked the RBI to drop its 'upper-layer NBFC' tag and allow it to stay private.

That means drug prices rose at a rate that far exceeded the 2024 inflation rate of 3%, the overall healthcare inflation rate ...

People with idiopathic hypersomnia sleep up to 18 hours daily yet never feel rested. New research reveals the devastating ...

Moderna's experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial ...

New analysis finds the median net price for 154 newly launched drugs, when adjusted for inflation and manufacturer discounts, ...

Amicus Therapeutics (FOLD) remains a Buy, driven by strong product momentum and new assets. Read here for more investment ...

Oura, the company behind the personal health tracker the Oura Ring, is exploring the potential for its device can detect ...

Adding to the pressure, demographic trends such as the rise in chronic disease and an aging population continue to increase ...

The company’s Moderate operating performance and financial health, combined with its High valuation, make the stock appear ...

The company based in Lexington County received its inspection report back from federal regulators. Here’s what it showed.

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Novo's lobbying efforts helped to convince 14 U.S. states to cover Wegovy for low-income patients under their Medicaid health ...